{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008732","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.405665+00:00","generated_at":"2026-06-07T15:34:13.030199+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phio raises $2.8M via warrant exercise at $1.33, issues new warrants at $1.08","bullets":["Existing warrant holders exercise 2,130,252 shares at reduced price of $1.33/share; gross proceeds ~$2.8M.","Phio issues new unregistered Series A and Series B warrants to purchase up to 4,260,504 shares at $1.08/share.","Series A warrants have a 5.5-year term; Series B warrants have an 18-month term.","H.C. Wainwright serves as exclusive placement agent; receives 7.5% cash fee and 159,769 placement agent warrants.","Net proceeds intended for working capital and general corporate purposes; offering expected to close Dec 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008732","json":"https://secwatch.observer/filing/0001683168-23-008732.json","markdown":"https://secwatch.observer/filing/0001683168-23-008732.md","text":"https://secwatch.observer/filing/0001683168-23-008732.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823008732/0001683168-23-008732-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823008732/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:34:13.030199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71c699ecec9136cd67973f977491d02b55ddac08","claim":"Phio Pharmaceuticals Corp. entered into Inducement Letter Agreement with certain holders valued at approximately $2.8 million (effective 2023-12-06).","evidence_excerpt":"On December 6, 2023, Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), entered into an inducement letter agreement (the “Inducement Letter Agreement”) with certain holders (the “Holders”) of certain of its existing warrants to purchase up to an aggregate of 2,130,252 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823008732/0001683168-23-008732-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain holders"},{"label":"Value","value":"approximately $2.8 million"},{"label":"Effective","value":"2023-12-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}